Table 1.
Demographic and clinical pre-systemic therapy/enrollment characteristics of older women with nonmetastatic breast cancer by cognitive outcomes
| Overall sample (n = 228) | No decline (n = 155) | Transient cognitive decline (n = 43) | Persistent cognitive decline (n = 30) | ||
|---|---|---|---|---|---|
|
|
|||||
| Predictor | Mean (SD) or percent (n) | P-valuea | |||
| Sociodemographic factors | |||||
| Age in years, mean (SD), range | 68.10 (5.64), 60.00-91.14 | 67.91 (5.55), 60.00-84.47 | 68.20 (5.77), 60.19–84.33 | 68.99 (6.04), 60.11–91.14 | .635 |
| Race, % (n) | .851 | ||||
| White | 82.02 (187) | 82.58 (128) | 79.07 (34) | 83.33 (25) | |
| Nonwhite | 17.98 (41) | 17.42 (27) | 20.93 (9) | 16.67 (5) | |
| Marital status, % (n) | .669 | ||||
| Married | 67.11 (153) | 68.39 (106) | 67.44 (29) | 60.00 (18) | |
| Widowed, divorced, single | 32.89 (75) | 31.61 (49) | 32.56 (14) | 40.00 (12) | |
| Mean education, years, mean (SD) | 15.82 (2.03) | 15.87 (2.02) | 15.67 (2.15) | 15.73 (1.96) | .831 |
| Clinical factors | |||||
| Treatment, % (n) | .733 | ||||
| Chemotherapy with our without hormonal therapy | 28.07 (64) | 29.03 (45) | 23.26 (10) | 30.00 (9) | |
| Hormonal therapy only | 71.93 (164) | 70.97 (110) | 76.74 (33) | 70.00 (21) | |
| AJCC v. 6 stage, % (n) | .453 | ||||
| 0 | 6.14 (14) | 6.45 (10) | 9.30 (4) | 0.00 (0) | |
| I | 68.42 (156) | 67.10 (104) | 67.44 (29) | 76.67 (23) | |
| II | 21.05 (48) | 21.29 (33) | 23.26 (10) | 16.67 (5) | |
| III | 4.39 (10) | 5.16 (8) | 0.00 (0) | 6.67 (2) | |
| Surgery type, % (n) | .253 | ||||
| BCS with/without RT | 66.08 (150) | 63.23 (98) | 76.74 (33) | 65.52 (19) | |
| Mastectomy | 33.92 (77) | 36.77 (57) | 23.26 (10) | 34.48 (10) | |
| ER status, % (n) | .871 | ||||
| Positive | 90.75 (206) | 90.32 (140) | 92.86 (39) | 90.00 (27) | |
| Negative | 9.25 (21) | 9.68 (15) | 7.14 (3) | 10.00 (3) | |
| HER2 status, % (n) | .110 | ||||
| Positive | 7.80 (17) | 10.07 (15) | 10.26 (4) | 6.67 (2) | |
| Negative | 92.20 (201) | 89.93 (134) | 90.70 (39) | 93.33 (28) | |
| Depression (≥16 on CES-D), % (n) | 9.87 (22) | 11.84 (18) | 9.30 (4) | 0.00 (0) | .154 |
| Mean STAIb score, mean (SD) | 28.49 (7.30) | 29.03 (7.86) | 27.98 (6.67) | 26.47 (4.42) | .189 |
| Mean FACT-Fc score, mean (SD) | 43.83 (7.78) | 43.93 (8.51) | 44.48 (4.98) | 42.42 (7.18) | .522 |
| BMI, mean (SD)e | 28.63 (6.40) | 27.90 (6.58) | 29.91 (6.28) | 30.61 (4.93) | .036 |
| Number of prescription drugs regularly taken, mean (SD) | 3.59 (2.06) | 3.38 (2.00) | 3.65 (2.17) | 4.60 (1.94) | .011 |
| ApoE4 status, % (n) | .002 | ||||
| ApoE4 Positive | 21.10 (46) | 14.29 (21) | 37.21 (16) | 32.14 (9) | |
| ApoE4 Negative | 78.90 (172) | 85.71 (126) | 62.79 (27) | 67.86 (19) | |
| Cardiovascular, % (n) comorbiditiesd (including peripheral vascular disease) | .010 | ||||
| Yes | 53.07 (121) | 46.45 (72) | 62.79 (27) | 73.33 (22) | |
| No | 46.93 (107) | 53.55 (83) | 37.21 (16) | 26.67 (8) | |
P-values reflect overall comparisons using analysis of variance (ANOVA) among groups. BCS = breast-conserving surgery; ER = estrogen receptor; CES-D = Center for Epidemiologic Studies Depression Scale; STAI = State Trait Anxiety Inventory, state version; FACT-F = Functional Assessment of Cancer Therapy—Fatigue Subscale; SD = standard deviation; CRCD = cancer-related cognitive decline.
State-Trait Anxiety Inventory scores range from 20 to 80; higher scores reflecting more anxiety.
FACT-Fatigue Subscale scores range from 0 to 52; higher scores reflect less fatigue.
Includes angina, arrhythmia, hypertension, heart attack, peripheral vascular disease, and other cardiovascular disease.
BMI = weight (kg)/height (m2) at baseline.